Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study

G. Saggu, D. Stroopinsky, A. Z. Dudek, A. J. Olszanski, D. Juric, A. Dowlati, U. Vaishampayan, H. Assad, J. Rodón, J. Gibbs, J. Green, Z. Du, R. Rudicell, K. Kannan, R. Gharavi, A. Gomez-Pinillos, R. J. Fram, A. Berger, K. Sachsenmeier, S. Kasar

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Fingerprint

Dive into the research topics of 'Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology